NZ533249A - Use of deoxypeganine for treating clinical depression - Google Patents

Use of deoxypeganine for treating clinical depression

Info

Publication number
NZ533249A
NZ533249A NZ533249A NZ53324902A NZ533249A NZ 533249 A NZ533249 A NZ 533249A NZ 533249 A NZ533249 A NZ 533249A NZ 53324902 A NZ53324902 A NZ 53324902A NZ 533249 A NZ533249 A NZ 533249A
Authority
NZ
New Zealand
Prior art keywords
deoxypeganine
depression
drug
use according
proportions
Prior art date
Application number
NZ533249A
Other languages
English (en)
Inventor
Joachim Moormann
Hermann Mucke
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of NZ533249A publication Critical patent/NZ533249A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NZ533249A 2001-12-21 2002-12-14 Use of deoxypeganine for treating clinical depression NZ533249A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10163667A DE10163667B4 (de) 2001-12-21 2001-12-21 Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
PCT/EP2002/014274 WO2003053445A1 (de) 2001-12-21 2002-12-14 Verwendung von desoxypeganin zur behandlung der klinischen depression

Publications (1)

Publication Number Publication Date
NZ533249A true NZ533249A (en) 2007-05-31

Family

ID=7710660

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ533249A NZ533249A (en) 2001-12-21 2002-12-14 Use of deoxypeganine for treating clinical depression

Country Status (29)

Country Link
US (1) US20050009813A1 (enExample)
EP (1) EP1461042B1 (enExample)
JP (1) JP2005513105A (enExample)
KR (1) KR100614504B1 (enExample)
CN (1) CN1283253C (enExample)
AR (1) AR037967A1 (enExample)
AT (1) ATE404203T1 (enExample)
AU (1) AU2002363874B2 (enExample)
BR (1) BR0215306A (enExample)
CA (1) CA2471338C (enExample)
CZ (1) CZ301210B6 (enExample)
DE (2) DE10163667B4 (enExample)
DK (1) DK1461042T3 (enExample)
EA (1) EA006896B1 (enExample)
ES (1) ES2312657T3 (enExample)
HU (1) HUP0402298A3 (enExample)
IL (2) IL162509A0 (enExample)
MX (1) MXPA04006125A (enExample)
MY (1) MY138088A (enExample)
NO (1) NO326446B1 (enExample)
NZ (1) NZ533249A (enExample)
PL (1) PL370315A1 (enExample)
PT (1) PT1461042E (enExample)
SI (1) SI1461042T1 (enExample)
SK (1) SK287152B6 (enExample)
TW (1) TWI241189B (enExample)
UA (1) UA76254C2 (enExample)
WO (1) WO2003053445A1 (enExample)
ZA (1) ZA200404053B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ATE359075T1 (de) * 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
JP5000932B2 (ja) * 2005-06-21 2012-08-15 日東電工株式会社 ニコチン含有経皮吸収製剤
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
CN101433565B (zh) * 2008-11-26 2013-06-05 上海中医药大学 骆驼蓬属种子总生物碱提取物和它们的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus

Also Published As

Publication number Publication date
AR037967A1 (es) 2004-12-22
PT1461042E (pt) 2008-11-03
WO2003053445A1 (de) 2003-07-03
DE10163667A1 (de) 2003-07-10
SK287152B6 (sk) 2010-01-07
UA76254C2 (en) 2006-07-17
EP1461042A1 (de) 2004-09-29
MXPA04006125A (es) 2005-05-16
ATE404203T1 (de) 2008-08-15
WO2003053445A8 (de) 2004-07-01
AU2002363874B2 (en) 2007-12-13
ES2312657T3 (es) 2009-03-01
KR20040068327A (ko) 2004-07-30
HUP0402298A2 (hu) 2005-02-28
HK1066742A1 (zh) 2005-04-01
EA006896B1 (ru) 2006-04-28
SI1461042T1 (sl) 2009-02-28
CN1604781A (zh) 2005-04-06
MY138088A (en) 2009-04-30
US20050009813A1 (en) 2005-01-13
BR0215306A (pt) 2004-12-21
TW200301124A (en) 2003-07-01
JP2005513105A (ja) 2005-05-12
CA2471338C (en) 2009-02-24
PL370315A1 (en) 2005-05-16
TWI241189B (en) 2005-10-11
DE50212649D1 (de) 2008-09-25
ZA200404053B (en) 2004-10-12
KR100614504B1 (ko) 2006-08-22
SK2582004A3 (en) 2004-12-01
AU2002363874A1 (en) 2003-07-09
CZ301210B6 (cs) 2009-12-09
IL162509A (en) 2010-06-16
CN1283253C (zh) 2006-11-08
DK1461042T3 (da) 2008-12-01
EP1461042B1 (de) 2008-08-13
NO326446B1 (no) 2008-12-08
HUP0402298A3 (en) 2011-03-28
IL162509A0 (en) 2005-11-20
EA200400751A1 (ru) 2004-12-30
NO20042476L (no) 2004-06-14
CA2471338A1 (en) 2003-07-03
CZ2004739A3 (cs) 2004-12-15
DE10163667B4 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
JP2003506484A (ja) 非常に低用量のシクロベンザプリンを使用する睡眠障害の処置または予防するための組成物使用
EP1503755A1 (en) Zonisamide use in obesity and eating disorders
JP2009543767A (ja) フリバンセリンとカフェインとを含む組成物、その調製方法及び薬剤としての使用
AU2002363874B2 (en) Use of desoxypeganine for treating clinical depression
KR19980701640A (ko) 약제 탐닉 환자 치료를 위한 멜라토닌의 사용
MXPA04006124A (es) Cabeza de cilindro.
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
MXPA04006126A (es) Acero para herramientas de arranque de viruta.
US20110065749A1 (en) Method and pharmaceutical composition for treatment of mental disorders
CA2338330A1 (en) Use of moclobemide for treating certain phsychiatric and medical disorders
JP2005306882A (ja) 感情的不安定の治療のための医薬の製造に有用な組成物
HK1066742B (en) Use of desoxypeganine for treating clinical depression
WO2025137348A1 (en) Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile
Kaushik et al. Overture of the sildenafil citrate gels and jellies: The simplified sight
JP2022546134A (ja) 自閉症スペクトル障害の治療における使用のためのバフィデムスタット
Dose Procaterol hydrochloride hydrate
WO1993016696A1 (en) Brofaromine as an agent for treating social phobia
OA16802A (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed